Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212016 | 0.82 | FDPS (0.42) | FDPSSMPD1PTPN1LAP3CA1 | |
| SCHEMBL210519 | 0.82 | SMPD1 (0.57) | FDPSSMPD1PTPN1LAP3S1PR2 | |
| SCHEMBL28818847 | 0.79 | TSHR (0.40) | FDPSSMPD1PLA2G2ALAP3CA1 | |
| SCHEMBL8609842 | 0.79 | FDPS (0.46) | FDPSSMPD1PTPN1LAP3CA1 | |
| SCHEMBL4059932 | 0.77 | SMPD1 (0.56) | FDPSSMPD1PTPN1LAP3S1PR2 | |
| SCHEMBL7840417 | 0.77 | SMPD1 (0.56) | FDPSSMPD1PTPN1LAP3S1PR2 | |
| SCHEMBL8682289 | 0.76 | SMPD1 (0.66) | FDPSSMPD1PTPN1LAP3S1PR2 | |
| SCHEMBL24922980 | 0.76 | SMPD1 (0.55) | FDPSSMPD1PLA2G2APTPN1LAP3 | |
| SCHEMBL22503349 | 0.76 | SMPD1 (0.55) | FDPSSMPD1PLA2G2APTPN1LAP3 | |
| SCHEMBL26273842 | 0.76 | SMPD1 (0.55) | FDPSSMPD1PLA2G2APTPN1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | FDPS 3701/4885SMPD1 235/4885PLA2G2A 584/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | FDPS 3701/4885SMPD1 235/4885PLA2G2A 584/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | FDPS 3701/4885SMPD1 235/4885PLA2G2A 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.